Top Markets
Coin of the day
Regnum Corp. Regnum Corp.

Regnum Corp.

RGMP
Rank in Stocks #42305
Regnum Corp. is dedicated to advancing and marketing therapeutic agents... Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV) from gaining entry into human cells. Headquartered in New York, New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$2.30K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regnum Corp. (RGMP)

Category

Operating Margin for Regnum Corp. (RGMP)
Operating Margin as of 2026 TTM: 0.00%
According to Regnum Corp. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Regnum Corp. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.97% -
US
28.81% -
NL
0.00% -
CH
31.23% -
BE
0.00% -
KR
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.